Zydus Lifesciences gets USFDA final approval for Ammonium Lactate Cream
News by Aliceblue News Desk
16 Feb 2026
Introduction
Leading pharmaceutical company received USFDA final approval for Ammonium Lactate Cream 12% for United States market with reported annual sales of USD 15 million.
Also Read: Biocon stock in green after Q3 profit jumps 5-fold to ₹144 Cr
Share price movement of Zydus Lifesciences
On February 16, 2026, Zydus Lifesciences Ltd opened at ₹904.80, down 0.01% from its previous close of ₹904.85. The stock reached a high of ₹916.00 (1.23%) and a low of ₹904.25. By 11:33 AM, it traded at ₹907.35, a 0.28% increase, with a market cap of ₹91,300.64 crore.
Zydus Gets USFDA Approval
Zydus Lifesciences Limited received final approval from the USFDA for Ammonium Lactate Cream, 12%. The product is a generic version of Lac-Hydrin Cream, 12% for United States market.
The cream treats xerosis and ichthyosis vulgaris. It will be manufactured at Changodar, Ahmedabad and distributed by Viona Pharmaceuticals Inc. Annual US sales were USD 15 million.
Stock performance of Zydus Lifesciences for period of 1 week, 6 months, and 1 year
Zydus Lifesciences Ltd declined 2.03% over the past week and fell 7.99% in six months. The stock gained 0.32% over the past one year.
Also Read: Welspun Corp shifts 100% ownership of KSA pipe company in $8M deal
Shareholding pattern of Zydus Lifesciences
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.10% | 7.30% | 7.10% |
| DII | 11.10% | 10.90% | 11.10% |
| Public | 6.90% | 6.80% | 6.70% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) is a global pharmaceutical company formed in 1995, focused on innovation and addressing unmet healthcare needs across multiple therapeutic segments.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Zydus Lifesciences Ltd share price rising today?
A: Zydus Lifesciences receives USFDA final approval for Ammonium Lactate Cream 12%; US annual sales stood at USD 15 million.
Q: What is Zydus Lifesciences Ltd’s main business focus?
A: Zydus Lifesciences Ltd develops, manufactures and markets pharmaceutical products across multiple therapeutic areas globally.
Q: What are the 52-week high and low of Zydus Lifesciences Ltd stock?
A: Zydus Lifesciences Ltd 52-week high is Rs.1,059.00 and 52-week low is Rs.797.05 on NSE.
News Author
Aliceblue News Desk
